Herbal immunomodulators as add on treatment in asymptomatic and mildly symptomatic COVID-19 confirmed cases: findings from a prospective single centre clinical trial

M. Ravi Kumar Reddy; K. R. Hari Venkatesh; J. Jothilakshmi

doi:10.18203/2319-2003.ijbcp20212073

Authors

M. Ravi Kumar Reddy Research and Development-Healthcare, Sriveda Sattva Private Limited (Sri Sri Tattva), Bengaluru, Karnataka, India
K. R. Hari Venkatesh Research and Development-Healthcare, Sriveda Sattva Private Limited (Sri Sri Tattva), Bengaluru, Karnataka, India
J. Jothilakshmi Research and Development-Healthcare, Sriveda Sattva Private Limited (Sri Sri Tattva), Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20212073

Keywords:

COVID-19, Immunity, RT-PCR, Sri Sri TattvaTM, Herbal immunomodulators

Abstract

Background: The aim of the present study was to evaluate safety and efficacy of Sri Sri Tattva^TMimmunity products, a combination of single herb and poly herb formulations in COVID-19 patients by assessing their clinical features and immune markers. The products when administered orally for a period of 14 days in COVID-19 patients demonstrated significant improvement in clinical symptoms.

Methods: Patients with fever, cough, sore throat started responding to the treatment from day 3 and most of the patients were clinically free of symptoms by day 7. Early recovery from signs and symptoms was observed in most of the patients. Sri Sri Tattva^TM immunity products has also demonstrated an excellent clinical improvement and immune markers including tumor necrosis factor (TNF-alfa), interleukin (IL-6), interferon (IFN-beta), D-dimer, ferritin, lactate dehydrogenease (LDH) and C-reactive protein (CRP) in COVID-19 patients.

Results: The final results of this study showed that Sri Sri Tattva^TM immunity products reduced the time to clinical cure and number of days in achieving negative real time polymerase chain reaction (RT-PCR) by early viral clearance when given along with standard of care thus reduced the duration of hospitalization.

Conclusions: In the present study, 82% of COVID-19 patients cleared the virus within 10-14 days of study period reducing the duration of hospitalization. None of the patients progressed to severe COVID-19 and succumbed to the disease. This clearly indicates that Sri Sri Tattva^TM immunity products when administered orally along with standard of care has definitive role in the management of COVID-19 patients.

Metrics

Metrics Loading ...

References

Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279(19):1548-53.

Tabish SA. Complementary and alternative healthcare: is it evidence-based? Int J Health Sci. 2008;2(1):21475465.

Mike S. Complementary and alternative medicine. Encyclopæd Britannica. 2018;3:1-48.

Gaudreau A, Hill E, Balfour HH, Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis. 1998;178(2):297-303.

Safrin S, Cherrington J, Jaffe HS. Cidofovir: review of current and potential clinical uses. Advan Experiment Med Biol. 1999;458:111-20.

Rajesh A, Chawla R, Marwah R, Arora P, Sharma RK, Vinod K. Potential of complementary and alternative medicine in preventive management of novel H1N1 flu (swine flu). Pandemic: thwarting potential disasters in the bud. Evid Based Complement Alternat Med. 2011;2011:586506.

Liang-Tzung L, Wen-Chan H, Chun-Ching L. Antiviral natural products and herbal medicines. J Tradition Complement Med. 2014;4(1):24-35.

Akshada AK, Rajendra CD, Chandrakant SM. Natural products in drug discovery. Pharmacog Med Plants. 2019.

Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. J Clin Virol. 2020;127:104346.

Xiaoqiang C, Longfei H, Yan Z, Weiyu H, Zhou L, Aiwu K. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-ncov infection. Biorxiv. 2020;2:931766

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-4.

Lei F, Liu Y, Zhou F, Quan J, Zhang P, Zhu L, et al. Longitudinal association between markers of liver injury and mortality in COVID‐19 in China. Hepatol. 2020;72(2):389-98.

Brandon MH, Gaurav A, Johnny W, Stefanie B, Jens V, Mario P, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Ame J Emerg Med. 2020;38(9):1722-6.

Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med. 2020;18(168):74.

Wenjie T, Xiang Z, Xuejun M, Wenling W, Peihua N, Wenbo X, et al. A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019−2020. China CDC Weekly. 2020;2(4):61-2.

Chaolin H, Yeming W, Xingwang L, Lili R, Jianping Z, Yi H. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506.